Atai Life Sciences (ATAI) Earnings Call Presentation

Business Combination Highlights - Non-atai Beckley Psytech shareholders will receive approximately 105 million newly issued shares of atai common stock, representing about 31% of the pro forma entity[14] - Closing is expected in the second half of 2025, pending atai shareholder approval[14] - Approximately 25% of atai's common stock has entered into voting agreements supporting the transaction[14] BPL-003 Clinical Trial Results and Design - Phase 1 results showed perceptual effects generally resolving in under 90 minutes[40] - Phase 2a Part 1 (Monotherapy Cohort) data showed a mean MADRS reduction of approximately 13 points at Day 2, sustained to Day 85[53] - In Phase 2a Part 1, 55% of patients met response criteria one day after a single 10mg dose of BPL-003[53] - In Phase 2a Part 1, 55% of patients met clinical remission criteria one month after a single dose, with 45% meeting remission criteria at day 85[53] - In Phase 2a, approximately 90% of drug-related AEs occurred on the day of dosing, and all were resolved without intervention[60] - Phase 2b clinical trial is a randomized, quadruple-masked, monotherapy study in approximately 196 moderate to severe TRD patients[62] Market Opportunity - SPRAVATO achieved blockbuster status in 2024 with sales exceeding $1 billion, with approximately 86% of sales in the US[24] - Johnson & Johnson highlights SPRAVATO as a "key franchise" guiding $3 billion to $3.5 billion in annual sales[28]